Company intelligence / Profile preview

Kaisa Health

Shenzhen, Guangdong, Chinahealthy.kaiserpermanente.org ↗

Ownership: Private
Development stage: Other

Overview

Kaisa Health holds rare pharmaceutical licenses in China and focuses on high-end biopharmaceuticals and psychoactive drugs. It owns Qinghai Pharmaceutical Factory—the only domestic producer of raw materials for morphine-type drugs with exclusive rights to 14 psychoactive drugs. The company also operates a chain of sports rehabilitation clinics and has established a complete dental medical industry chain through acquisitions such as Mega Medical and Basic Implant. Its products are commercialized in China.

Therapeutic areas: PsychiatryNeurologyOther
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Kaisa Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaisa Health.

Explore the full profile